<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03642210</url>
  </required_header>
  <id_info>
    <org_study_id>M360-L105</org_study_id>
    <nct_id>NCT03642210</nct_id>
  </id_info>
  <brief_title>Study of a Levonorgestrel 52 mg Intrauterine System for the Treatment of Heavy Menstrual Bleeding</brief_title>
  <official_title>A Phase 3, Multicenter, Open-Label Study of a Levonorgestrel 52 mg Intrauterine System for the Treatment of Heavy Menstrual Bleeding</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medicines360</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medicines360</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the efficacy of a levonorgestrel 52 mg intrauterine system as a treatment for heavy
      menstrual bleeding.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a multicenter, open-label, evaluation of the efficacy and safety of LNG20 IUS
      for treatment of heavy menstrual bleeding.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2018</start_date>
  <completion_date type="Anticipated">February 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Successful treatment</measure>
    <time_frame>6 months</time_frame>
    <description>End of treatment menstrual blood loss &lt;80 ml and 50% or less than baseline</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Menorrhagia</condition>
  <arm_group>
    <arm_group_label>Levonorgestrel 52 mg intrauterine system</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Levonorgestrel 52 mg intrauterine system</intervention_name>
    <description>Levonorgestrel 52 mg intrauterine system</description>
    <arm_group_label>Levonorgestrel 52 mg intrauterine system</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Reports subjectively heavy menses for most menses when not using hormonal
             contraception or a copper IUD

          -  Healthy females 18-50 years old, inclusive, at the time of enrollment

          -  Typical menstrual cycle length of 21-35 days or less with variation from cycle to
             cycle of typically 5 days of less

          -  Has menstrual blood loss in 2 or the 3 cycles during the screening phase with greater
             than or equal to 80 mL per cycle as measured by the Alkaline Hematin Method

          -  Willing to use a medication other than a NSAID as first-line treatment for any pain
             condition during the duration of study participation

          -  Willing to abstain from heterosexual intercourse or use acceptable contraception
             during the screening phase; acceptable contraception includes male or female permanent
             contraception, withdrawal (if has been used as current method prior to screening) or a
             barrier method

        Exclusion Criteria:

          -  Currently pregnant

          -  Planning to attempt to become pregnancy during the screening and treatment phases of
             study participation (i.e., up to approximately 11 months after consent)

          -  Currently lactating or not having a subjectively heavy menses since discontinuation of
             lactation prior to screening

          -  Clinical diagnosis of perimenopause (in the opinion of the investigator) based on one
             or more of the following: changes in menstrual regularity (e.g., shorter, longer,
             absent, irregular), hot flashes, sleeping disorder, or changes in mood (e.g.,
             depression, nervous tension, and irritability) within 3 months prior to or during the
             screening period

          -  Screening blood laboratory value outside of the normal range that, in the the opinion
             of the investigator, requires treatment or further work-up (i.e., are considered
             clinically significant)

          -  Has poor venous access or significant history of inability to have blood samples drawn

          -  History of bicornuate uterus or any other abnormality of the uterus resulting in
             distortion of the uterine cavity or cervical canal incompatible with insertion

          -  Prior (documented within 6 months) or baseline study ultrasound examination
             demonstrating:

               1. a congenital or acquired uterine anomaly that distorts the uterine cavity or
                  cervical canal incompatible with insertion;

               2. endometrial polyps (unless previously removed);

               3. fibroids meeting any of the following criteria: i. distort the uterine cavity or
                  cervical canal incompatible with insertion; ii. submucosal location; iii.
                  exceeding 2 cm in the greatest dimension for any individual fibroid; iv. more
                  than three fibroids of a least 1.5 cm in greatest diameter

               4. clear evidence of adenomyosis

          -  Chronic endometritis on endometrial biopsy at screening

          -  Has any of the following premalignant or malignant diseases:

               1. malignant melanoma

               2. acute malignancies affecting blood or leukemias

               3. gestational trophoblastic disease (unless at least one year with undetectable
                  beta-hCG)

               4. known or suspected cervical, ovarian, vaginal or vulvar cancer

               5. uterine cancer or evidence of uterine malignancy, endometrial intraepithelial
                  neoplasia (EIN) or hyperplasia on an endometrial biopsy at screening (an
                  endometrial biopsy performed within 6 months of Visit 1 could be used if a report
                  is available with a tissue diagnosis)

               6. history of breast cancer, or suspicion of breast cancer until proven otherwise

          -  Has any of the following medical conditions:

               1. bleeding diathesis (inherited or acquired)

               2. history of von Willebrand's disease or other known coagulopathy

               3. uncontrolled significant hypertension defined as a sitting systolic blood
                  pressure greater than or equal to 160 mm Hg or diastolic blood pressure greater
                  than or equal to 95 mm Hg at any screening or enrollment visit

               4. presence or history of venous thromboembolic diseases (deep vein thrombosis,
                  pulmonary embolism), presence or history of arterial thromboembolic diseases
                  (e.g., myocardial infarction, stroke)

               5. uncontrolled thyroid disorder

               6. sickle cell anemia

               7. diabetes mellitus that is poorly controlled or with end-organ/vascular
                  complications

               8. hyperprolactinemia at screening

               9. acute or severe liver disease or liver tumor

              10. history of or poorly controlled bipolar disorder, schizophrenia, psychosis, major
                  depressive disorder or other major psychiatric disorder according to the criteria
                  of the Diagnostic and Statistical Manual of Mental Disorders

              11. history of a positive HIV test or having a partner who is known to be HIV
                  positive

          -  Use of antifibrinolytics, platelet aggregation inhibitors, anticoagulants or other
             similar medications that can increase or decrease bleeding within 30 days prior to and
             during the screening (EXCEPTION: NSAIDs can be used a second-line treatment for pain
             management)

          -  Use of intrauterine or implantable contraception, progestin-only pills, combined
             hormonal contraceptives or oral progestin therapy within 30 days before screening

          -  Depomedroxyprogesterone acetate (DMPA) injection within the past 9 months prior to
             screening

          -  Use of non-contraceptive estrogen, progesterone, progestin, testosterone, androgen or
             other gonadotropins (e.g. hCG) within 30 days before screening

          -  Prior total or partial endometrial ablation or resection

          -  History of a uterine aspiration or curettage procedure for any indication (other than
             an office biopsy) within 4 weeks of screening
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrea Olariu, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Chief Medical Officer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MomDoc Women's Health Research</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85251</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danielle Gincastro, MA, CRC</last_name>
      <phone>480-305-7423</phone>
      <email>daniellegincastro@momdoc.com</email>
    </contact>
    <investigator>
      <last_name>Harris</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>OB/GYN Research, University of California, Davis Health</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bridget Little</last_name>
      <phone>916-734-6846</phone>
      <email>hs-obgynresearch@ucdavis.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wr-McCr, Llc</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>T. Chang</last_name>
      <phone>619-521-2841</phone>
      <email>tchang@mccresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stanford University Medical Center, OB-GYN Clinic</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>K. Lerma</last_name>
      <phone>650-721-1562</phone>
      <email>klerma@stanford.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Colorado Denver</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Seale</last_name>
      <phone>303-724-2013</phone>
      <email>rebecca.seale@ucdenver.edu</email>
    </contact>
    <contact_backup>
      <last_name>Eva Dindinger</last_name>
      <phone>1-303-724-8482</phone>
      <email>eva.dindinger@ucdenver.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>UF Health Women's Specialists</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melanie S Bentley, CCRP</last_name>
      <phone>904-633-0772</phone>
      <email>melanie.bentley@jax.ufl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Comprehensive Clinical Trials, LLC</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33409</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Emory University School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valerie Jean</last_name>
      <phone>404-778-1358</phone>
      <email>vjean@emory.edu</email>
    </contact>
    <contact_backup>
      <last_name>Sarah Cordes</last_name>
      <phone>1-404-778-1358</phone>
      <email>smdicke@emory.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>CR Prime</name>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <zip>83404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Study Coordinator</last_name>
      <phone>208-270-6638</phone>
      <email>nora@crprime.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Bayview Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katrina Thaler</last_name>
      <phone>410-550-8506</phone>
      <email>Kstouff3@jhmi.edu</email>
    </contact>
    <contact_backup>
      <last_name>Barbara Chase</last_name>
      <phone>1-410-955-5692</phone>
      <email>bchase@jhmi.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Michigan Women's Hospital</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meg Urbin</last_name>
      <phone>734-647-1040</phone>
      <email>megurbin@med.umich.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University in St. Louis School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristen Powers</last_name>
      <phone>314-747-2196</phone>
      <email>kpowers@wustl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rex Garn Mabey</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89128</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashlee Ross</last_name>
      <phone>702-242-8800</phone>
      <email>ashleeross.research@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Women's Health Research Center</name>
      <address>
        <city>Lawrenceville</city>
        <state>New Jersey</state>
        <zip>08648</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Lee</last_name>
      <phone>609-799-5010</phone>
      <email>slee@scottedermd.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>M3 Wake Research, Inc.</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tevnan Keller</last_name>
      <phone>919-781-2514</phone>
      <email>tkeller@wakeresearch.com</email>
    </contact>
    <contact_backup>
      <last_name>Sarah Nichols</last_name>
      <phone>9197812514</phone>
      <email>snichols@wakeresearch.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati Physicians Company</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M. Thomas, MD</last_name>
      <phone>513-584-4100</phone>
      <email>researchforwomen@uchealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospitals Cleveland Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bridget Ermlich</last_name>
      <phone>216-844-8091</phone>
      <email>bridget.ermlich@uhhospitals.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katherine Martin</last_name>
      <phone>614-293-0075</phone>
      <email>kathryn.martin@osumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reed Sheridan</last_name>
      <phone>503-494-7051</phone>
      <email>sheridar@ohsu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Lecks</last_name>
      <phone>215-349-5201</phone>
      <email>klecks@obgyn.upenn.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jessica McClucky</last_name>
      <phone>215-615-4206</phone>
      <email>Jessica.McClusky@uphs.upenn.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Sendeck</last_name>
      <phone>215-955-9243</phone>
      <email>Stephanie.sendeck@jefferson.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Magee-Womens Hospital, Center for Family Planning</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kara Armbruster</last_name>
      <phone>412-641-3418</phone>
      <email>bumbernickkl2@upmc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Tennessee Medical Center</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Suttles, RN</last_name>
      <phone>865-305-7915</phone>
      <email>asuttles@utmck.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>WR-Medical Research Center of Memphis</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Blair Longserre</last_name>
      <phone>919-781-2514</phone>
      <email>blongserre@mrcofmemphis.com</email>
    </contact>
    <contact_backup>
      <last_name>LaShonda Herndon</last_name>
      <phone>9197812514</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Nunuez</last_name>
      <phone>832-824-0403</phone>
      <email>Maria.Nunez@bcm.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Orr</last_name>
      <phone>801-213-2774</phone>
      <email>amy.orr@hsc.utah.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Eastern Virginia Medical-Conrad Clinical Research Center</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jamie Evans</last_name>
      <phone>757-446-7972</phone>
      <email>evansjl@evms.edu</email>
    </contact>
    <contact_backup>
      <last_name>Elizabeth Strode</last_name>
      <phone>1-757-446-7087</phone>
      <email>strodeel@evms.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>August 20, 2018</study_first_submitted>
  <study_first_submitted_qc>August 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 22, 2018</study_first_posted>
  <last_update_submitted>February 13, 2020</last_update_submitted>
  <last_update_submitted_qc>February 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Menorrhagia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levonorgestrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

